Category: Life Sciences
Global Life Sciences
-
Cellular Concrete
... CAGR of 5.3% over the analysis period 2024-2030. Building Materials, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$1.5 Billion by the end of the analysis ... Read More
-
Digital Diabetes Management
... at a CAGR of 18.6% over the analysis period 2024-2030. Devices, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$46.7 Billion by the end of the ... Read More
-
Glaucoma Surgery Devices
... at a CAGR of 21.0% over the analysis period 2024-2030. Traditional, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$3.1 Billion by the end of the ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis period. ... Read More
-
Insulin Storage Devices
... at a CAGR of 7.5% over the analysis period 2024-2030. Battery Operated Devices, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$996.0 Million by the end ... Read More
-
IR Spectroscopy
... CAGR of 5.1% over the analysis period 2024-2030. Benchtop, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$647.6 Million by the end of the analysis period. ... Read More
-
Local Anesthesia Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Lidocaine, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Microelectronic Medical Implants
... at a CAGR of 8.0% over the analysis period 2024-2030. Pacemakers & Defibrillators, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$22.7 Billion by the end ... Read More
-
Mid-Revenue Cycle Management / Clinical Documentation Improvement
... expected to reach US$8.0 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Solutions, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and ... Read More
-
Precision Medicine
... CAGR of 8.7% over the analysis period 2024-2030. Diagnostics, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$89.0 Billion by the end of the analysis period. ... Read More
-
Pre-Workout Supplements
... CAGR of 7.0% over the analysis period 2024-2030. Powder, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$25.7 Billion by the end of the analysis period. ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Radiodermatitis
... 4.2% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$412.0 Million by the end of the analysis period. Growth in ... Read More
-
X-ray Inspection Systems
... at a CAGR of 6.0% over the analysis period 2024-2030. Digital Imaging, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$925.2 Million by the end of ... Read More
-
Precision Medicine Software
... at a CAGR of 10.0% over the analysis period 2024-2030. On-Premise, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$2.6 Billion by the end of the ... Read More
-
Probiotics Dietary Supplements
... at a CAGR of 5.8% over the analysis period 2024-2030. Capsules, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$4.2 Billion by the end of the ... Read More
-
Protein Sequencing
... CAGR of 2.9% over the analysis period 2024-2030. Mass Spectrometry, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$973.5 Million by the end of the analysis ... Read More
-
Soft Tissue Repair
... at a CAGR of 6.0% over the analysis period 2024-2030. Fixation Products, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$19.6 Billion by the end of ... Read More
-
Translucent Concrete
... CAGR of 41.3% over the analysis period 2024-2030. Concrete, one of the segments analyzed in the report, is expected to record a 42.2% CAGR and reach US$118.5 Million by the end of the analysis period. ... Read More
-
Custom Antibody
... CAGR of 9.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$320.3 Million by the end of the analysis ... Read More
-
Fashion Face Masks
... at a CAGR of 16.3% over the analysis period 2024-2030. Anti-Pollution, one of the segments analyzed in the report, is expected to record a 15.9% CAGR and reach US$2.8 Billion by the end of the ... Read More
-
Flow Imaging Microscopy/Dynamic Image Analysis
... Million by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$34.7 Million by ... Read More
-
Food Enzymes
... CAGR of 6.1% over the analysis period 2024-2030. Microorganisms, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.6 Billion by the end of the analysis period. ... Read More
-
Intracranial Aneurysm
... CAGR of 8.7% over the analysis period 2024-2030. Endovascular Coiling, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Mammalian Polyclonal IgG Antibody
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Metabolic Markers, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$532.1 Million by the ... Read More
Research Assistance
